Navigation Links
Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Date:10/4/2007

tect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...lif., Nov. 20 Bionovo, I...present results from the Phase 1B,clinical trial ...ic breast,cancer, BZL101, at the Society for Inte... in Atlanta, Georgia. The Company,s oral presenta...ill be presented as a part of the Best of the,SIO...
(Date:11/20/2008)...rway, November 20 The Scandinavian...as announced results of studies on its,lead antim...Washington, DC,the studies showed that the novel...cidal effect, significantly better towards killing... than marketed gold standard drugs. In,addition t...
(Date:11/19/2008)...N.Y., Nov. 19 Biotech scientists i...toxicology research to better understand the effec...systems, reports Genetic Engineering & Biotec...ted in figuring out a new compound,s mechanism of ...cology technique, according to the November 15 iss...
(Date:11/18/2008)...Nov. 18 Arlington Medical Resource...e for the pharmaceutical and diagnostic,imaging i...ing,s Privigen was,sold in the U.S. during the th... of intravenous immune globulin (IVIG) and was lau...duct created from the blood plasma of thousands,o...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2CryoCath to present at Piper Jaffray and BMO Healthcare conferences 6960 1CryoCath to present at Piper Jaffray and BMO Healthcare conferences 6960 2Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 1Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 2Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 3Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals 6955 1Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals 6955 2Sosei Announces Update on Phase I Trials for SD118 6953 1Sosei Announces Update on Phase I Trials for SD118 6953 2Sosei Announces Update on Phase I Trials for SD118 6953 3
(Date:11/21/2008)...abor , , FRIDAY, Nov. 21 (HealthDay News... activates the uterine muscles for contraction dur...es for preterm labor. , The molecule prostacyc...f these uterine muscle cells, keeping them relativ...rs from Dartmouth Medical School in New Hampshire,...
(Date:11/21/2008)...anuary 8, 2009 , , TORONTO, Nov. 21 /PRNews...edEmerg") (OTCBB: MDER), one of Canada,s leading p...it has obtained an interim order from the Ontario ...y announced plan of arrangement (the "Arrangement"...will acquire all of MedEmerg,s outstanding shares....
(Date:11/21/2008)...Health Science Center at Houston will launch a new...XAS), to promote geriatrics training for physician...Donald W. Reynolds Foundation and $1.25 million in...riatric medicine principles to everyone from the m...s. With the reach of Lyndon B. Johnson General Hos...
(Date:11/21/2008)... -- Heska Corporation,(Nasdaq: HSKA ) today ann...,Security Analysts, 12th Annual Biotech and Specia... Avenue of the Americas, 2nd Floor in New York, NY...a.m. Eastern Time (7:35 a.m.,Mountain Time) and w...s,following the presentation through a link under...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
... Hospital doctors warn that children playing footb... from blisters caused by football boots // . Acco... toxic shock syndrome in the UK have been attribut...in children. However if misdiagnosed or left untre...
...ch is already running in a loss would have to pay ...s they are not in a position // to fulfil the comm...tem for the health services. The trusts in the so...d 50 full-time employees to help develop the ?20bn...
...radesh has decided to take action against erring P...has now fixed the number of patients //to be treat...y health centres so as to stop the 'popular' pract...eave the hospital early, at least an hour before t...
...as announced at the Cheltenham Science Festival th... mount Everest to conduct //a research into the ef...cientists from the Centre for Aviation, Space and ...nstitute of Human Health and Performance, Universi...
Other Medicine News:Health News:Budding Footballers at Risk from Blood Infection 2Health News:Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project 2Health News:UP Government Fixes Work Schedules for Provincial Medical Service Doctors 2Health News:Mount Everest to be Site of Research into Hypoxia 2
Since 1991 Intersurgical Incorporated manufactures high efficiency breathing filters, heat and moisture exchangers, ventilator circuits, oxygen therapy products, hand-held nebulizers and an extensive
...The Ulti-Mist™ HME product line has the righ...to adults and from intubated patients to patients ...humidification for both anesthesia and critical ca...ers provide maximum protection for patients and st...
...These hygroscopic condenser humidifiers (HCH) capt...turn them in the inspired gas. Small and compact, ...ic and hygroscopic benefits. Depending on the tida...small-volume model., ,The adult HCH is ideal for ...
...These hygroscopic condenser humidifiers (HCH) capt...turn them in the inspired gas. Small and compact, ...ic and hygroscopic benefits. Depending on the tida...small-volume model., ,The adult HCH is ideal for ...
Medicine Products: